Research ArticleArticle
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease
Tomoyuki Fujisawa, Hironao Hozumi, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui and Takafumi Suda
The Journal of Rheumatology May 2019, jrheum.180825; DOI: https://doi.org/10.3899/jrheum.180825
Tomoyuki Fujisawa
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Hironao Hozumi
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Hideki Yasui
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Yuzo Suzuki
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Masato Karayama
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Kazuki Furuhashi
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Noriyuki Enomoto
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Yutaro Nakamura
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Naoki Inui
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
Takafumi Suda
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease
Tomoyuki Fujisawa, Hironao Hozumi, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, Takafumi Suda
The Journal of Rheumatology May 2019, jrheum.180825; DOI: 10.3899/jrheum.180825
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease
Tomoyuki Fujisawa, Hironao Hozumi, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, Takafumi Suda
The Journal of Rheumatology May 2019, jrheum.180825; DOI: 10.3899/jrheum.180825